LCS
BNTX icon

Levin Capital Strategies’s BioNTech BNTX Stock Holding History

Levin Capital Strategies’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,000
Closed -$277K – 306
2020
Q3 		$277K Buy
+4,000
New +$287K 0.04% 203

Other funds holding BNTX

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Levin Capital Strategies's BNTX Position: Q4 2020 in Review

Levin Capital Strategies sold out of BioNTech (BNTX) in Q4 2020, closing a stake of 4,000 shares — an estimated $277K sold.

Levin Capital Strategies first reported a position in BNTX in Q3 2020 and held it in 1 quarter. The position peaked at $277K in Q3 2020. 194 funds tracked by Wall St. Rank hold BNTX as of Q4 2020.

  • Levin Capital Strategies reported no remaining BioNTech position as of Q4 2020 after selling out during the quarter.
  • Levin Capital Strategies sold 4,000 BioNTech shares in Q4 2020, an estimated $277K.
  • Levin Capital Strategies first reported a position in BioNTech in Q3 2020 and held it in 1 quarter.
  • Levin Capital Strategies's BioNTech position peaked at $277K in Q3 2020.
  • 194 funds tracked by Wall St. Rank held BioNTech as of Q4 2020.

Based on Levin Capital Strategies's 13F filing for Q4 2020, filed 16 Feb 2021.